TITLE

CHEMEQ DRUG ACTIVE AGAINST GASTRIC ULCER GERM

PUB. DATE
April 2003
SOURCE
Worldwide Biotech;Apr2003, Vol. 15 Issue 4, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the development of an antimicrobial drug that kills a strain of the gastric ulcer germ, Helicobacter pylori which is resistant to antibiotics, by pharmaceutical company Chemeq Ltd, as of April 2003.
ACCESSION #
9427667

 

Related Articles

  • Protein Interaction Domain Mapping for the Selection of Validated Targets and Lead Compounds in the Anti-Infectious Area. Legrain, P.; Strosberg, D. // Current Pharmaceutical Design;Jun2002, Vol. 8 Issue 13, p1189 

    Despite considerable progress in the analysis of microbial genomes, the number of validated targets suitable for the development of drugs acting on agents causing infectious diseases remains modest. The diversity of new chemical entities specific for such targets has almost not increased over...

  • Yearly prevalence of primary metrodinazole and clarithromycin resistance of H. pylori: a prospective study in consecutive out-patients (Brussels 1995-2001). Burett, A.C.; Vandenborre, C.; Goutier, S. // Gut;Sep2002 Supplement 2, Vol. 51, pA92 

    Aim of the Study: The main determinants of anti-H. pylori (Hp) treatment success are patient compliance and the antimicrobial susceptibility of the infecting strains. The aim of this study is to follow the local prevalence of primary resistance to M and C in Hp isolates in Brussels. Method: All...

  • Traditional and Non-Traditional Antimicrobial Agents for H. Pylori Infection. Kato, Mototsugu; Hokari, Kaku; Kagaya, Hideotoshi; Takeda, Hiroshi; Sugiyama, Toshiro; Asaka, Masahiro // Current Pharmaceutical Design;Oct2000, Vol. 6 Issue 15, p1575 

    Triple therapy with a proton pump inhibitor plus two antibiotics is recently standard regimen for treatment of H. pylori infection. However, the agents that are used for H. pylori eardication are not always limited to drugs whose primary use is as an antimicrobial agent. Anti-H. pylori activity...

  • Past Antibiotic Use Affects Resistance and Outcomes of Helicobacter pylori Infection. Mcmahon, B.J.; Hennessy, T.W.; Bensler, J.M.; Bruden, D.L.; Parkinson, A.J.; Morris, J.M.; Reasonover, A.L.; Huriburt, D.A.; Bruce, M.G.; Sacco, F.; Butler, J.C. // Annals of Internal Medicine;9/16/2003, Vol. 139 Issue 6, pI10 

    Helicobacter pylori is a common type of bacteria that usually infects people during their childhoods. In most cases, the infection does not cause problems. However, some people with H. pylori infection get inflammation or ulcers in the stomach or upper intestine. Doctors treat inflammation and...

  • Reality and false premises of antimicrobial susceptibility testing for Helicobacter pylori. Miwa, Hiroto; Sato, Nobuhiro // Journal of Gastroenterology;2003, Vol. 38 Issue 5, p519 

    Focuses on the antimicrobial susceptibility shown by the bacteria Helicobacter pylori. Resistance shown by the pylori strains towards clarithomycin; Relationship of metronidazole-resistant strains with the treatment failures; Influence of CAM resistance on the efficacy of proton pump inhibitor...

  • Antibiotic Treatment Strategies for Helicobacter pylori Infection. Campo, S. M. A.; Zullo, A.; Hassan, C.; Morini, S. // Recent Patents on Anti-Infective Drug Discovery;Jan2007, Vol. 2 Issue 1, p11 

    In the third decade of the Helicobacter pylori era several informations are available on its pathogenetic mechanisms, as well as on therapeutic approaches. A 7-14 day triple or quadruple regimens (proton pump inhibitor together with 2 antibiotics) are currently suggested as first-line treatment,...

  • TRIPLE THERAPY AND DUODENAL ULCER HEALING: MORE EVIDENCE FOR THE "H" FACTOR. Lawson, Mark; Johnson, David A.; Cattau Jr., Edward L. // American Journal of Gastroenterology;Feb1992, Vol. 87 Issue 2, p255 

    Examines the effectiveness of triple antimicrobial therapy in healing Helicobacter pylori-induced duodenal ulcer. Information on the drug treatment; Response of the patients to the treatment; Cost of triple therapy.

  • H pylori might protect children from asthma. Tanday, Sanjay // GP: General Practitioner;4/27/2007, p2 

    The article reports on the findings of the U.S. researchers who have discovered that Helicobacter (H) pylori might protect children from asthma. The findings suggest that giving antibiotics to children early in life might make them more susceptible to asthma by reducing levels of H pylori in the...

  • Clarithromycin resistance in Helicobacter pylori: implications for therapy.  // Journal of Gastroenterology;2000, Vol. 35 Issue 1, p69 

    Editorial. Discusses the implications for therapy of clarithromycin (CAM) resistance in Helicobacter (H.) pylori. Antimicrobial drugs that are used to eradicate H. pylori; Problem in the treatment of H. pylori infections; Eradication rate in patients infected with CAM-susceptible H. pylori.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics